CORAL SPRINGS, Florida, November 29, 2016 /PRNewswire/ --
As the legal marijuana industry continues to see high levels of competition within the marketplace, Cannabis operators in the sector are executing strategies by developing innovative services and products as well as acquiring resources and other assets to leverage the substance's momentum behind increased legalization after the recent election season. Active companies today include: Marapharm Ventures Inc. (OTC: MRPHF), Terra Tech Corp (OTC: TRTC), Cannabis Sativa, Inc. (OTC: CBDS), PharmaCyte Biotech, Inc. (OTC: PMCB) and INSYS Therapeutics, Inc. (NASDAQ: INSY).
Marapharm Ventures Inc. (OTCQB: MRPHF) (CSE: MDM.CN) announces the purchase of the remaining 25% equity interest in EcoNevada, LLC, ("EcoNevada"), a private company based in Las Vegas, Nevada, such that Marapharm now owns 100% of the issued and outstanding shares of EcoNevada. EcoNevada has provisional marijuana licenses and special use permits over 204,000 square feet of cultivation and 16,000 square feet of production. Read this full Press Releases and recent news for Marapharm at http://financialnewsmedia.com/profiles/mrphf.html
"We have now completed the deal which was made a year ago, when we purchased control of EcoNevada. The price for the minority position of 25% was 100,000 shares of Marapharm, as agreed to in the original transaction, to suit the needs of the sellers for tax and other reasons. Since recreational use of marijuana has been legalized in the state of Nevada, EcoNevada has increased in value to Marapharm, both as an asset and as a main vehicle to drive revenue in Nevada." said Linda Sampson, CEO of Marapharm.
"We just bought the adjoining 1.1 acres to the 5.9 acres we acquired, in order to accommodate parking requirements from the City of North Las Vegas to allow for the three licenses to be consolidated on one property," added Linda Sampson. In addition, further to its November 23, 2016, news release, Marapharm reports it is in advanced discussions with several large casinos in Las Vegas for the placement of automated cannabis machines (ACMs) in casinos. It is proposed that the ACMs will stock and only sell Marapharm products from its 380,000-square-foot facility located in Las Vegas. There is no guarantee that such discussions will result in any agreements or be fruitful or beneficial to Marapharm.
TERRA TECH CORP (OTCQX: TRTC) based in Newport Beach , a cannabis-focused agriculture company yesterday announced that Derek Peterson , Chief Executive Officer, will present live at VirtualInvestorConferences.com on December 1, 2016 . View investor presentations 24/7 at http://www.virtualinvestorconferences.com. - View investor presentations 24/7 at http://www.virtualinvestorconferences.com. More - DATE: Thursday, December 1, 2016 - TIME: 12:15 pm ET - LINK: http://tinyurl.com/1201prepr
Cannabis Sativa, Inc. (OTCQB: CBDS) was up slightly on Tuesday at $5.59 by 11:46am EDT. Cannabis Sativa, Inc., through its subsidiaries, develops, manufactures, and sells herbal based skin care products in the United States and internationally.
PharmaCyte Biotech, Inc. (OTCQB: PMCB) was up over 30% at $0.068 on Tuesday trading over 15.9 Million shares by 11:46am EDT. PharmaCyte Biotech, a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that a Pre-Investigational New Drug (Pre-IND) meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has been granted by the FDA. During the meeting with representatives from CBER, they will respond to PharmaCyte's previously submitted questions to the FDA as part of a Pre-IND information package related to PharmaCyte's clinical trial in locally advanced, inoperable pancreatic cancer (LAPC)
INSYS Therapeutics, Inc. (NASDAQ: INSY) was up slightly on Tuesday at $12.79 by 11:46am EDT. Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated four thousand nine hundred dollars for news coverage of the current press release issued by Marapharm Ventures Inc. by a non-affiliated third party. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
SOURCE FN Media Group, LLC